Last edition
News about "Nivolumab biosimilar"
Zydus Launches World's First Nivolumab Biosimilar 'Tishtha' in India
Zydus Lifesciences has launched Tishtha, the world’s first biosimilar of the immunotherapy drug nivolumab, in India, aimed at expanding access to advanced cancer care by offering the treatment at nearly one-fourth the cost of the reference product for patients with multiple cancer types.
Nivolumab Biosimilar | 23/01/2026 | By News Bureau | 458
Zydus Challenges Delhi HC Order Blocking Sale of Cancer Drug Biosimilar
The single-judge order, issued on July 18, 2025, prohibits Zydus from manufacturing, selling, advertising, importing, or exporting its Nivolumab biosimilar until the final outcome of the case or the expiry of the suit patent on May 2, 2026.
Nivolumab Biosimilar | 25/07/2025 | By Darshana | 622
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy